ETFs
T
TSHA
Taysha Gene Therapies, Inc.
4.120
+0.180+4.57%Opening13:02 10/20 EDT
OPEN/PREV CLOSE3.950/3.940
TODAY RANGE3.890-4.195
VOL3.41M
MARKET CAP1.34B
52 WEEK RANGE3.455-7.30
AVG VOL (3M)3.37M
% TURNOVER1.05%
TURNOVER--
P/E (TTM)-9.9855
% RANGE7.74%
EPS(TTM)-0.4126
P/E(FORWARD)-8.0784
P/B3.461
BVPS1.191
DIVIDEND--
P/S120.12
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.21B
SHARES OUTSTANDING325.83M
NEXT EARNINGS11/02-11/06
FREE FLOAT293.23M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·13h ago
Taysha Gene Therapies (TSHA) After Early Rett Data With An Undervalued Narrative
Simply Wall St·1d ago
Does Rett Trial Progress Change The Bull Case For Taysha Gene Therapies Stock?
Simply Wall St·10/09 05:32
Taysha Gene Therapies (TSHA) Could Be 66% Undervalued On Rett Syndrome Hopes
TipRanks·09/17 11:20
Taysha Gene Therapies initiated with an Outperform at Wolfe Research
Seeking Alpha·09/11 15:11
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
TipRanks·08/24 00:08
Taysha Gene Therapies Earnings Call Highlights Pivotal Progress
Simply Wall St·08/20 04:45
TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA)
The Motley Fool·08/18 23:13
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
Simply Wall St·08/13 21:41
Taysha Gene Therapies (TSHA) Stock Retreats As Cash Burn Deepens
Simply Wall St·08/13 08:30
Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return
TipRanks·08/12 14:35
Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)
Same Industry
Name/Symbol
Change%
Price